Amgen
Search results
After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world. [9] Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen. [10]
Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Aug 19, 2022 · Biogen IDEC is a biotechnology company that develops and commercializes innovative therapies for serious diseases. Learn about its news highlights, cancer research, early careers and more.
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Idec, a biotechnology company, adopted a new corporate identity and logo in March 2015. The name change reflects its heritage, focus and commitment to patients and science in neurology, immunology and hematology.
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen Idec, a biotechnology company, announced in 2010 that it would focus on neurology and biologics, exit cardiovascular and oncology, and reduce costs and headcount. The company also said it would pursue strategic partnerships and personalized medicine for MS patients.
